Stuart L. Goldberg, MD

Stuart L. Goldberg, MD

Stuart L. Goldberg MD is Chief Scientific Officer at Cota and Associate Clinical Professor of Medicine at Rutgers: The New Jersey Medical School.  In addition to directing the scientific efforts of Cota, a real world data and analytics company he co-founded, Dr. Goldberg also maintains an active clinical practice in the Division of Leukemia at the John Theurer Cancer Center at Hackensack University Medical Center. 

Dr. Goldberg obtained his medical degree at the Pennsylvania State University and fellowships in hematology-oncology and bone marrow transplantation at George Washington University Medical Center and the Mayo Clinic.  An experienced clinical researcher, he has published over 200 papers and a dozen book chapters, with a focus on chronic myelogenous leukemia and myelodysplastic syndromes.  He is a member of the steering committee for the Simplicity Study, the largest observational international study of real world experience in CML. He also is a member of the development board for the MDS Foundation, the largest patient advocacy organization focusing on this marrow failure disorder, and has lectured widely on transfusional iron overload complications.  For these efforts he was awarded the 2015 David King Clinical Scientist Award by the Association of Community Cancer Centers (ACCC).  In the field of “big data” analysis he has used Medicare and MarketScan databases to redefine the incidence and complications related with myelodysplastic syndromes (published in JCO and Transfusion) and has reviewed observational databases to foster adherence with evidence based CML monitoring guidelines (published in JOP, CRMO and CLML).  

More recently he has used the Cota database to explore rates and implications of EGFR mutational testing among community oncologists, gaps in the diagnostic evaluation of colon cancer, and cost-effectiveness of genomic profiling in lower risk breast cancer.  His current scientific efforts at Cota revolve around demonstrating how a more precise digital disease classification schema (the Cota Nodal Address) can drive healthcare value within emerging payment reform models.